UNITED STATES   
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
  
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
For the month of November 2023
Commission File No.:001-35773
 
REDHILL BIOPHARMA LTD.
(Translation of registrant’s name into English)
 
21 Ha'arba'a Street, Tel Aviv, 6473921, Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F         Form 40-F 
 
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ 
 
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____


 
RedHill Biopharma Ltd. (the “Company”) announces today the adjournment of the Extraordinary General Meeting of Shareholders scheduled for November 16, 2023, due to a lack of required legal quorum.

The Company’s Board of Directors has approved the postponement of the Extraordinary General Meeting of Shareholders to November 29, 2023, at 3:00 p.m. Israel time, to be held at the offices of the Company at 21 Ha'arba'a Street, Tel-Aviv, Israel. All votes submitted to The Bank of New York Mellon, as depositary for the American Depositary Shares, must be received by 12:00 p.m. EST, on November 24, 2023.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845) and on June 29, 2023 (File No. 333-273001) and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on July 29, 2021 (File No. 333-258259), August 4, 2023 (File No. 333-273709) and on October 13, 2023 (File No. 333-274957), as amended.


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 
 
 
REDHILL BIOPHARMA LTD.
 
 
(the "Registrant")
 
 
 
 
 
Date: November 16, 2023
By:
/s/ Dror Ben-Asher
 
 
Name:
 Dror Ben-Asher
 
 
Title:
Chief Executive Officer
 

 


Redhill Biopharma (NASDAQ:RDHL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Redhill Biopharma.
Redhill Biopharma (NASDAQ:RDHL)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Redhill Biopharma.